Stockscreener 앱 받기
0.6871
1.14%
-0.00795
시간 외 거래:
.69
0.00295
+0.43%
전일 마감가:
$0.695
열려 있는:
$0.7
하루 거래량:
65,358
Relative Volume:
0.39
시가총액:
$1.06M
수익:
$743.00K
순이익/손실:
$-7.63M
주가수익비율:
-0.229
EPS:
-3
순현금흐름:
-
1주 성능:
+4.65%
1개월 성능:
-33.30%
6개월 성능:
-49.85%
1년 성능:
-74.55%
1일 변동 폭
$0.68
$0.70
1주일 범위
$0.67
$0.7031
52주 변동 폭
$0.632
$3.12
캔 파이트 바이오파마 Stock (CANF) Company Profile
명칭
Can-Fite Biopharma Ltd ADR
전화
972 3 924 1114
주소
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
CANF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
0.6871 | 9.99M | 743.00K | -7.63M | 0 | -3.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
캔 파이트 바이오파마 Stock (CANF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2017-08-11 | 개시 | Maxim Group | Buy |
| 2016-10-19 | 재개 | ROTH Capital | Buy |
| 2016-08-29 | 재개 | Rodman & Renshaw | Buy |
| 2015-11-30 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-31 | 재확인 | H.C. Wainwright | Buy |
| 2015-03-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-29 | 재확인 | ROTH Capital | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
모두보기
캔 파이트 바이오파마 주식(CANF)의 최신 뉴스
What indicators show strength in Enterprise Products Partners L.P. Limited PartnershipIn-Depth Stock Trading Volume Analysis - Newser
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial By Investing.com - Investing.com South Africa
Can-Fite reaches 50% enrollment milestone in pancreatic cancer trial - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs - Investing.com
Can-Fite BioPharma prices $5 million public offering of ADSs By Investing.com - Investing.com India
Harbour Energy Begins First Oil Production From Maria Phase 2 - The Globe and Mail
Can Fite Biopharma stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.14 - Investing.com
Can Fite Biopharma stock hits 52-week low at $1.22 By Investing.com - Investing.com South Africa
Can Fite Biopharma stock hits 52-week low at $1.22 - Investing.com
Can-Fite BioPharma announces $3M registered direct offering - Investing.com
Can-Fite’s Surging Stock: Is It Time to Act? - timothysykes.com
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits - GlobeNewswire Inc.
Can Fite Biopharma stock hits 52-week low at $1.86 - Investing.com
Can-Fite's partner Vetbiolix secures $325M deal for dog arthritis drug - Investing.com
List of Israeli Stocks Traded on the NYSE Worth Considering - The Times of Israel
Martingale Risk – Philips Shareholders Group Action to be Filed in the Netherlands - Business Wire
Can-Fite BioPharma seeks FDA nod for NASH drug trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire UK
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat - Yahoo Finance
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
bioAffinity Technologies Inc Stock Price Today | NASDAQ: BIAF Live - Investing.com
4 Penny Stocks On Robinhood To Buy Under $4 Now; Worth The Risk? - Penny Stocks
New Lenovo Research: People are Working More by Not Going to Work, but Worry about Home Tech, Data Security and Personal Costs - Business Wire
10 Biopharmaceutical Companies Trying To Cure Cancer - Yahoo Finance
Can-Fite's Rheumatoid Arthritis Drug Faces Off With Methotrexate In Phase III Trial For $40 Billion Market (NYSE:CANF) - Seeking Alpha
Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement - Business Wire
캔 파이트 바이오파마 (CANF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):